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Abstract
Despite recent advances in targeted therapies, patients with pancreatic adenocarcinoma continue to have poor survival
highlighting the urgency to identify novel therapeutic targets. Our previous investigations have implicated chemokine
receptor CXCR4 and its selective ligand CXCL12 in the pathogenesis and progression of pancreatic intraepithelial neoplasia
and invasive pancreatic cancer; hence, CXCR4 is a promising target for suppression of pancreatic cancer growth. Here, we
combined in silico structural modeling of CXCR4 to screen for candidate anti-CXCR4 compounds with in vitro cell line assays
and identified NSC56612 from the National Cancer Institute’s (NCI) Open Chemical Repository Collection as an inhibitor of
activated CXCR4. Next, we identified that NSC56612 is structurally similar to the established anti-malarial drugs chloroquine
and hydroxychloroquine. We evaluated these compounds in pancreatic cancer cells in vitro and observed specific
antagonism of CXCR4-mediated signaling and cell proliferation. Recent in vivo therapeutic applications of chloroquine in
pancreatic cancer mouse models have demonstrated decreased tumor growth and improved survival. Our results thus
provide a molecular target and basis for further evaluation of chloroquine and hydroxychloroquine in pancreatic cancer.
Historically safe in humans, chloroquine and hydroxychloroquine appear to be promising agents to safely and effectively
target CXCR4 in patients with pancreatic cancer.
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Introduction
Pancreatic duct cancer is a uniformly fatal disease that is
frequently diagnosed with distant metastasis at the time of initial
clinical presentation. Unrecognized early disease and a highly
invasive phenotype are primary factors for the poor prognosis
associated with pancreatic cancer and highlight the urgency to
identify molecular targets for the progression of the disease.
Recently, the interactions between chemokines and their corre-
sponding receptors have been examined in the pathogenesis,
progression, and metastasis of pancreatic cancer [1,2,3]. These
studies have suggested that antagonists to chemokine receptor
CXCR4 may abrogate the invasive phenotype of pancreatic
cancer [4,5,6]. Despite increasing evidence to the importance of
CXCR4 in pancreatic cancer and other malignancies, antagonists
to CXCR4 that are safe and effective for clinical use remain
lacking.
Chemokine CXCL12 (also known as stromal-derived factor-1a,
SDF-1a) activates multiple downstream effector pathways upon
binding its receptor CXCR4 [7]. The CXCL12-CXCR4
interaction regulates chemotaxis, adhesion, and secretion of
growth factors among many of its known functions [8]. Shortly
after CXCR4 was identified as a co-receptor for HIV-1 and HIV-
2 [9,10], the small bicyclam molecule AMD3100 was identified as
a specific CXCR4 antagonist [5]. AMD3100 has now been widely
used to investigate and interrogate CXCL12-CXCR4 interactions
[7]. Although AMD3100 remains in clinical use for stem cell
mobilization, its chronic administration has been associated with
significant cardiotoxicity [11]. Interestingly, recent studies have
shown that in addition to its role as an antagonist to CXCR4
signaling, AMD3100 paradoxically binds and activates chemokine
receptor CXCR7 [12,13].
Since current data suggests that AMD3100 may not be safe or
effective as an anti-CXCR4 antagonist for therapeutic applications
in pancreatic cancer, specific antagonists remain to be identified
for this purpose. In this interdisciplinary investigation, we
combined in silico modeling of CXCR4 structure with high-
throughput screening and in vitro assays in pancreatic cancer cell
lines to identify novel antagonists to CXCR4-mediated cell
proliferation in pancreatic cancer cells. Our study shows that the
safe and efficacious anti-malarial drugs chloroquine and hydroxy-
chloroquine are effective CXCR4 antagonists that suppress
pancreatic cancer cell proliferation.
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Computational Modeling of CXCR4
The structural ensemble of the wild-type CXCR4 receptor was
predicted using the ab initio structure prediction method (Mem-
bStruk4.3) [14,15]. We compared the binding of mono and
bicyclam compounds to our predicted structures with mutagenesis
data to validate our computational predictions [16]. Our
predictions were submitted to the protein structure assessment
competition (GPCRDOCK2010) prior to the characterization of
the crystal structure of CXCR4 [17]. A detailed comparison of the
predicted structure with the crystal structure has verified the
accuracy of our modeling and has been published elsewhere
(Figure 1) [18].
We performed virtual ligand screening (VLS) of the National
Cancer Institute’s (NCI) Open Chemical Repository Collection for
3 different predicted conformations of CXCR4. Next, the
candidate small molecules were filtered based on their proximity
to residues that play an important role in antagonist binding,
namely: D92 (TM2), H121 (TM3), D171 (TM4), E262 (TM6) and
E288 (TM7) [19,20]. Approximately 90% of the small molecules
were excluded at this step.
Binding energies of the small molecules were then calculated
and the top 10% of the small molecules with the lowest binding
energies were retained. The chemical structures in the top 10%
of the hits ranged from multi-aromatic ring structures to
structures with longer alkyl chains. The primary criterion for
further selection was the interaction of the candidate molecules
with the residues that are known to be important for antagonist
binding [16]. These molecules were then examined for pro-
tein-ligand contacts and 50 candidate small molecules were
selected from approximately 350,000 molecules for experimen-
tal testing.
NSC56612 and Related Compounds Inhibit CXCR4-
Mediated Signaling
Of the 50 candidate compounds from VLS, we were able to
procure 32 from the NCI for experimental testing. Screening of
the 32 compounds was performed using the Tango assay that tests
the inhibition of the CXCL12-mediated recruitment of b-arrestin
to the carboxy terminus of CXCR4. This assay identified one hit
compound that suppressed b-arrestin recruitment and the
chemical structures of this compound NSC56612 is shown in
Figure 2. We further performed a gamut of direct ligand binding,
secondary messenger calcium flux, and downstream chemotaxis
assays mediated by the CXCR4/CXCL12 axis to verify that these
compounds are directly targeting CXCR4. NSC56612 was used as
a template to identify compounds with similar chemical structures.
This lead to identification of three other compounds that are anti-
malarial agents: chloroquine, hydroxychloroquine, and quinacrine
(Figure 2).
Figure 3A shows the concentration dependence curve of the
direct inhibition of fluorescently labeled CXCL12 binding by
NSC56612, chloroquine, hydroxychloroquine, and quinacrine.
Competitive binding experiments showed that these compounds
directly inhibit binding of CXCL12 to CXCR4 with low micro-
molar affinity. The assay wherein b-arrestin-2 recruitment
mediated by CXCL12 is assessed also showed inhibition by these
three compounds with low micro-molar efficacy (Figure 3B).
Figure 3B also shows inhibition by AMD3100, a CXCR4
antagonist.
Calcium flux, a secondary messenger to CXCL12-mediated
activation of CXCR4, measures the activation of CXCR4. The
CXCL12-mediated calcium flux was measured at two different
concentrations of the four compounds, namely 100 mM and
200 mM. As seen in Figure 3C, NSC56612, chloroquine, and
hydroxychloroquine showed 50% to 60% inhibition of CXCL12-
induced calcium flux, while quinacrine showed less than 10%
inhibition (data not shown). We measured the level of inhibition
by these compounds to chemotaxis, a downstream effect in
CXCR4-expressing cells. Figure 3D shows the effect of the
compounds in chemotaxis assays wherein the inhibition of
CXCL12-induced cell migration is measured. To assess the
concentration of compounds necessary for chemotaxis inhibition,
we performed a dose-dependent inhibition of chemotaxis of the
lead compound NSC56612 as shown in Figure 4. All four
compounds showed 40% to 50% reduction in CXCL12-induced
cell migration. Quinacrine showed substantial efficacy towards
inhibiting chemotaxis (data not shown), while it had little or no
effect on the calcium flux assay. Since quinacrine did not suppress
CXCL12-mediated calcium flux, it was omitted from further
analysis in pancreatic cancer cell lines. The results of these assays
show that chloroquine and hydroxychloroquine directly inhibit
CXCR4 signaling.
Figure 1. Comparison of the predicted structural model of
CXCR4 (yellow) with the crystal structure (pink). The small
molecule designated ‘‘1t’’ is placed into the predicted binding site. The
root mean square deviation of the predicted and crystal structures is
2.5 A ˚, which demonstrates close alignment of our predicted model with
the established crystal structure. Accordingly, the predicted location of
the binding site of the small molecule ‘‘1t’’ matched with the crystal
structure. The small molecule ‘‘1t’’ is depicted as small spheres.
doi:10.1371/journal.pone.0031004.g001
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Mediated ERK Phosphorylation
In a previous investigation, we discovered that CXCL12
induced an increase in ERK phosphorylation [21]. Although
exposure to CXCL12 also activated the PI-3K/AKT pathway, the
degree to which AKT phosphorylation was altered was much
lower than ERK phosphorylation. Therefore, we focused our
investigation in this study on ERK activation. First, we verified
that CXCL12 induces an increase in phospho-ERK in pancreatic
cancer cell lines (Figure 5A). Then, we demonstrated that
chloroquine and hydroxychloroquine exert dose-dependent inhib-
itory effects on CXCL12-mediated ERK phosphorylation in
PANC-1 and AsPC-1 cells (Figure 5B). Finally, we show the
quantitative analysis of the inhibition in phospho-ERK in
Figure 5C.
Chloroquine and Hydroxychloroquine Trigger Apoptosis
and Inhibit CXCL12-Mediated Proliferation and Anti-
Apoptosis
Chloroquine and hydroxychloroquine cytotoxicity in pancreatic
cancer cell lines was assessed and the IC50s were determined
(Figure 6). Using these values, we evaluated CXCR4 signaling in a
cell proliferation assay. We previously observed CXCR4-mediated
increases in cell proliferation in pancreatic cancer cells [21].
Therefore, chloroquine and hydroxychloroquine were assessed for
antagonism of CXCR4-mediated cell proliferation; and we
observed that both agents effectively antagonized CXCR4-
mediated cell proliferation in PANC-1, Hs-766T, and MIA-
PaCa-2 cells (Figure 7). Since increased proliferation was not
observed in AsPC-1 cells after exposure to CXCL12, these cells
were not assessed with chloroquine and hydroxychloroquine in
this assay. Our results are consistent with published reports which
show that not all pancreatic cancer cell lines respond to CXCL12
with increased proliferation [2]; the mechanism responsible for this
has not yet been elucidated. Both chloroquine and hydroxychlor-
oquine showed reduction in phospho-ERK in the presence of
CXCL12, with the total ERK concentration being unaffected.
These results show that chloroquine and hydroxychloroquine
specifically inhibit CXCR4-mediated signaling to suppress cell
proliferation in pancreatic cancer cells.
Since the mechanism for changes in cell proliferation was not
clear, we also assessed apoptosis following exposure to chloroquine
and hydroxychloroquine. First, our results suggest that CXCL12
promotes anti-apoptosis in pancreatic cancer cells. These results
are consistent with previously published reports for the CXCL12/
CXCR4 axis [22,23]. Second, our results indicate that chloro-
quine and hydroxychloroquine abrogate CXCL12-mediated anti-
apoptosis (Figure 7D), wherein pretreatment with chloroquine or
hydroxychloroquine increased apoptosis in PANC-1 cells.
Discussion
Using a cross-disciplinary approach starting with computa-
tional modeling of the CXCR4 receptor structure to in vitro
analysis of CXCR4 signaling, our study has determined that
chloroquine and hydroxychloroquine act as novel CXCR4
inhibitors in pancreatic cancer cells. We have demonstrated that
these clinically safe and effective anti-malarial agents specifically
inhibit binding of CXCL12 to CXCR4 and inhibit CXCL12-
CXCR4 downstream effector pathways that mediate calcium
flux, recruitment of ß-arrestin-2 and cell migration. In pancreatic
cancer cell lines we determined that chloroquine and hydroxy-
chloroquine block CXCL12-mediated signaling through the
Figure 2. Chemical structures of the NCI compound and structurally similar anti-malarial drugs used in this study. (A) NCI compound
NSC56612, (B) chloroquine, (C) hydroxychloroquine, and (D) quinacrine.
doi:10.1371/journal.pone.0031004.g002
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proliferation. Since CXCR4 appears to have an important role in
the pathogenesis and progression of pancreatic cancer [1,2,3],
our work has important clinical implications in the identification
of a novel therapeutic use for these established anti-malarial
agents.
Our initial studies required the accurate characterization of the
structure of CXCR4. Using computational methods previously
developed by us, we predicted the three-dimensional structure of
CXCR4 and the binding sites of known small molecule
antagonists such as cyclam compounds [16,24,25]. Our structural
predictions were performed prior to the publication of the crystal
structure of CXCR4 [17]. Subsequent comparison of the
predicted structures to the crystal showed an excellent agreement
of the root mean square deviation in coordinates of the ligand of
2.2 A ˚. These results were encouraging to further our study
looking for small molecule CXCR4 antagonists in pancreatic
cancer cells. With the predicted conformations of CXCR4, we
used established libraries of compounds to identify candidate
antagonist hits. Limiting the hits to the top 32 candidates, we
performed high-throughput screening assays, which further
narrowed our candidate list to 3 compounds. These initial
studies led us to NCI compound NSC56612. Exploration of the
chemical structure of NSC56612 for similar compounds via
public and commercial databases revealed that NSC56612
shared structural homology to chloroquine, hydroxychloroquine,
and quinacrine; but only chloroquine and hydroxychloroquine
passed all of our screening assays. The disparate efficacy of
quinacrine could be secondary to the heterogeneity of down-
stream effectors (e.g., phospholipase C or G-proteins) for different
cellular functions, which may result in variable response between
cells. Other studies have previously demonstrated differential
efficacy of discrete G protein coupled receptor ligands for
different assays [26,27]. To identify the putative binding sites of
these compounds we docked chloroquine and hydroxychloro-
quine to the crystal structure of CXCR4 (Figure 8) and identified
that the tertiary amine groups in these compounds make
hydrogen bonds with D97 on TM2 and E32 in the amino
Figure 3. NSC56612, chloroquine, and hydroxychloroquine inhibit CXCL12-mediated activity. (A) Concentration dependent inhibition of
fluorescently labeled CXCL12 (60 nM) binding to SNAP-tagged CXCR4 receptor in HEK293 cells by NSC56612, chloroquine, and hydroxychloroquine.
The half maximal effective concentrations (EC50), the values at which maximum CXCL12-CXCR4 binding is inhibited by 50%, for AMD3100, NSC56612,
chloroquine, and hydroxychloroquine are 60.0 nM, 5.5 mM, 6.1 mM, and 9.8 mM, respectively. These curves are representative data from 3 experiments
performed in duplicate. (B) Dose-dependent inhibition of CXCL12-induced b-arrestin-2-mediated beta-lactamase activity in engineered Tango assay
by pretreatment with AMD 3100, NSC56612, chloroquine, and hydroxychloroquine. Emission data at 460/530 was defined as the response ratio.
These curves are representative data from 3 experiments performed in duplicate. (C) Dose-dependent inhibition of CXCL12-induced intracellular
calcium flux by AMD 3100, NSC56612, chloroquine, hydroxychloroquine. The CXCR4-mediated calcium influx was measured at 1 mM of AMD3100 and
two different concentrations (100 mM and 200 mM) of the three compounds in Molt-4 cells. AMD 3100, NSC56612, chloroquine, and
hydroxychloroquine showed 50 to 60% inhibition of CXCL12-induced calcium influx. These curves are representative data from 3 experiments
performed in duplicate. (D) Inhibition of CXCL12-induced Jurkat cell migration in by AMD3100 (100 nM), NSC56612 (100 mM), chloroquine (100 mM),
and hydroxychloroquine (100 mM). All four compounds showed 40% to 50% reduction in CXCL12-induced cell migration. The figure shows data from
4 experiments performed in duplicate. Error bars represent 6 one SD. Student t-test: *,0.05 and **,0.01.
doi:10.1371/journal.pone.0031004.g003
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and Y255 show favorable van der Waals interaction with the
aromatic ring system in these compounds.
Since the invasive phenotype associated with CXCR4 is a
manifestation of CXCL12-driven signaling pathways, we tested
chloroquine and hydroxychloroquine in vitro. We chose to evaluate
Figure 4. NSC56612, chloroquine, and hydroxychloroquine inhibit CXCL12-induced migration in a dose-dependent manner. Cells
were plated in culture plates fitted with 8-uM pore membranes to create upper and lower cell culture chambers. Cells were plated in the upper
chamber and CXCL12 (30 nM) alone or with the addition of NSC56612, chloroquine, or hydroxychloroquine was placed in the bottom chamber. The
number of cells that migrated through the membrane in 5 hours was counted. Data shown is from 4 experiments performed in duplicate. Relative
changes in cell migration are depicted with the control condition serving as 100% migration. Error bars represent 6 one SD.
doi:10.1371/journal.pone.0031004.g004
Figure 5. Chloroquine and hydroxhychloroquine inhibit CXCL12-mediated ERK phosphorylation. (A) Immunostaining for phospho-ERK
was performed for PANC-1, Hs-766T, AsPC-1, and MIAPaCa-2 cell lysates. Cells were pretreated with chloroquine or hydroxychloroquine (0.1 mM) for
30 minutes after which cells were exposed to CXCL12 (200 ng/ml) for 20 minutes. An antibody to total ERK1/2 was used as a loading control. The
CXCL12-mediated increases in phospho-ERK were effectively abrogated with either chloroquine or hydroxychloroquine. (B) Pretreatment of PANC-1
and AsPC-1 cells with chloroquine and hydroxychloroquine (0.1–10 mM) for 5 minutes followed by exposure to CXCL12 (200 ng/ml) demonstrate
dose-dependent effects of drug treatment on CXCL12-mediated ERK phosphorylation. (C) Western blots were scanned and quantified using the
AlphaImager Tm3400 (Alpha Innotech). Fold changes for phospho-ERK compared to untreated controls were calculated as relative expression, which
was normalized to protein band intensities of total ERK. The data shows the mean of triplicate experiments, with p-values,0.05 considered
statistically significant.
doi:10.1371/journal.pone.0031004.g005
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demonstrated its role in mediating growth and proliferation in
pancreatic intraepithelial neoplasia and pancreatic cancer cells
[21]. In our current studies we observed effective inhibition of
CXCL12-driven ERK phosphorylation and inhibition of
CXCL12-mediated proliferation in vitro.
There is clinical evidence for the anti-cancer effects of
chloroquine and hydroxychloroquine. In a clinical trial for
glioblastoma multiforme, chloroquine was administered along
with conventional chemotherapy as adjuvant therapy in patients
who underwent surgical resection for glioblastoma multiforme.
The patients who received chloroquine experience improved
survival compared to patients who received chemotherapy alone
[28]. Although they did not identify CXCR4 as a potential target,
Rubin et al., had previously shown that CXCR4 antagonism
inhibited glioblastoma multiforme growth, suggesting that
CXCR4 was an appropriate target for glioblastoma therapy
[29]. Additionally, a clinical trial for metastatic colorectal cancer
has incorporated hydroxychloroquine along with standard cyto-
toxic chemotherapy [30]. Our group and others have examined
CXCR4 expression in colorectal cancer and observed a potential
role for CXCR4 in colorectal cancer progression [4,31,32]. Our
study demonstrates that chloroquine and hydroxychloroquine are
antagonists to CXCR4 and thus provides a molecular basis for
using chloroquine in patients with metastatic colorectal cancer.
Since this clinical trial is ongoing, the results have yet to mature.
Chloroquine has also been recently tested in vivo in a murine
pancreatic cancer model demonstrating tumoricidal effects with
improved survival [33]. However, these investigators used
chloroquine without an understanding of its effects on CXCR4.
Although chloroquine and hydroxychloroquine have been
recently used for anti-cancer applications, they were originally
formulated as anti-malarial agents. These drugs were formulated
because Atabrine, the first synthetic anti-malarial compound,
had undesirable side-effects of staining the skin and eyes [34].
Both chloroquine and hydroxychloroquine are weak bases that
target blood cells that are infected by malaria [35]. These drugs
work by preferentially diffusing into the parasite’s vacuole where
hemoglobin is broken down [36]. In the acidic vacuole, they
become protonated and trapped [36]. Within the vacuole, they
inhibit the breakdown of heme, the byproduct of parasitic
degradation of hemoglobin [36]. The accumulation of heme
becomes toxic and leads to cell lysis and death of the parasite
[36]. Aside from these anti-malarial indications, the mechanism
for the anti-neoplastic effects of chloroquine and hydroxychlor-
oquine have been examined [37]. Chloroquine appears to inhibit
autophagy and induce p53-dependent apoptosis [38]; and may
also enhance the effects of chemotherapy or radiation therapy
[39].
In conclusion, using a cross-disciplinary approach we identified
novel CXCR4 antagonists and have shown that chloroquine and
hydroxychloroquine inhibit CXCL12-CXCR4 signaling. Given
that effective antagonists to CXCR4 are lacking and that novel
therapies have yet to improve survival beyond 1-year for patients
with metastatic pancreatic cancer [25,40,41], our results have
important clinical implications. Our study results provide a
scientific basis for using chloroquine or hydroxychloroquine in a
pancreatic cancer trial; and since the safety profiles are well
established for these drugs, a clinical trial can be expeditiously
implemented for patients with pancreatic cancer.
Figure 6. Kill curves for chloroquine and hydroxychloroquine treatment of pancreatic cancer cells. AsPC-1, Hs-766T, MIAPaCa-2, and
PANC-1 cells were treated with a dose range of chloroquine or hydroxychloroquine (0.01–10 mM) at 72 hours to determine the half maximal
inhibitory concentration (IC50 values) of these compounds. AsPC-1 and Hs-766T cells had similar IC50 values for chloroquine and
hydroxychloroquine, whereas MIAPaCa-2 and PANC-1 cells had higher IC50 values for hydroxychloroquine than chloroquine.
doi:10.1371/journal.pone.0031004.g006
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Prediction of the CXCR4 Structure
MembStruk4.3, the ab initio structure prediction method, was
used to generate an ensemble of wild-type human CXCR4
structures [14,15]. The trans-membrane (TM) regions of CXCR4
were predicted using the Tm2ndS method with multiple sequence
alignment of human, rat, and mouse CXC and CC family of
chemokine receptors (Table 1) [14]. We optimized the relative
rotation and translation of the seven TM helices and the helical
kinks beginning from an assembled bundle of canonical helices
built from the TM predictions. Canonical right-handed a-helices
were built for each helix and their helical axes were oriented in
space according to the 7.5 A ˚ low-resolution electron density map
of frog rhodopsin [42].
This 7.5 A ˚ electron density map provided the positions and
relative orientations of the helical axes that served to optimize the
helical bundle. The relative translational orientations of the 7
helices were optimized by aligning the hydrophobic maximum
determined for each helix to a plane. The rotational orientation
was optimized using a combination of hydrophobic moments and
molecular dynamic techniques. Data from the crystal structure of
CXCR4 [17], which was only recently characterized, was not used
for these predictions.
We derived an ensemble of low energy TM barrel conforma-
tions for CXCR4 and its constitutively active mutants [43]. The
receptor conformations were selected to have the maximum
number of inter-helical hydrogen bonds and the highest total
energy of the protein conformation in a lipid bilayer. Three
potential low energy conformations were selected for CXCR4 that
Figure 7. Chloroquine and hydroxychloroquine decrease CXCL12-mediated proliferation in pancreatic cancer cell lines. (A) PANC-1,
(B) Hs-766T, and (C) MIAPaCa-2 cells were pretreated with chloroquine or hydroxychloroquine (0.1 mM) for 30 minutes after which cells were exposed
to CXCL12 (200 ng/ml) for 72 hours. (D) Pretreatment with chloroquine and hydroxychloroquine also triggered apoptosis and decreased CXCL12-
mediated apoptosis in PANC-1 cells. The data show the mean of triplicate experiments. P-values,0.05 were considered statistically significant.
doi:10.1371/journal.pone.0031004.g007
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different conformations: 2 had different orientations of the residue
Y219
5.58, which correspond to the 2 different orientations of
Y223
5.58 in rhodopsin and opsin crystal structures [44,45]. TM7
had 2 different helical orientations, where the position of E288
7.39
was different.
Docking of AMD3100 and Virtual Ligand Screening
The predicted binding site of the mono and bicyclam
derivatives of AMD3100 on CXCR4 was validated using
established site-directed mutagenesis data [19,20]. This predicted
binding site was then used to perform virtual ligand screening
(VLS) to identify new antagonist hits for CXCR4. The National
Cancer Institute’s (NCI) Open Chemical Repository Collection
[46], which is composed of approximately 300,000 compounds,
was queried using the Maestro LigPrep module (Schro ¨dinger; San
Diego, CA). Multiple conformations of candidate ligands were
then docked into the predicted binding site of CXCR4 using Glide
SP (Schro ¨dinger) scaling the van der Waals radii to 0.5 and partial
charge cutoff to 0.15. The combined Coulombic and van der
Waals energy cutoffs were then raised to 100 kcal/mol. The
charged molecules were eliminated and the neutral molecules that
were considered better candidates were selected for further
investigation. The docked ligand conformations for neutral
molecules were then filtered based on the buried surface area,
wherein ligands that were .80% buried and based on their
distances to the acidic residues D171, D262, and E288 were
selected. These 3 residues have been shown to be important in
binding CXCR4 antagonists [19,20].
Using the Prime module in Maestro, the side-chains within 5 A ˚
radius of the ligand were reassigned. Following the side-chain
reassignment, the binding energies (BE) of each docked confor-
mation was calculated using BE=PE (ligand in fixed protein) - PE
(ligand in solvation), where PE (ligand in fixed protein) is the
potential energy of the ligand calculated with the protein atoms
fixed and PE (ligand in solvation) is the potential energy of the
ligand calculated with the Surface Generalized Born continuum
solvation method [47]. The top 200 conformations of each set
were then visually inspected to maximize favorable receptor
interactions. We then selected the top 50 compounds from each
CXCR4 receptor conformation for subsequent testing.
Fluoresence Labeled Competitive Ligand Binding Assay
Competitive binding studies to evaluate candidate CXCR4
antagonists were performed using the chemokine CXCR4
receptor ligand binding assay kit according to manufacturer’s
instructions (Tag-lite, Cisbio; Bedford, MA) [48,49]. Briefly, HEK-
293 cells were incubated at room temperature for 2 hours with the
fluorescent-labeled CXCL12 ligand with or without the CXCR4
antagonists. After incubation, the cells were excited at 620 nm and
recorded at dual-emissions (620 nm and 665 nm) using PHER-
Astar (BMG LABTECH Inc.; Cary, NC). The relative ratios of
CXCL12-CXCR4 binding were obtained by dividing the acceptor
signal (665 nm) by the donor signal (620 nm) and multiplying this
value by 10,000.
CXCR4 Recruitment of b-arrestin
Activation of the CXCL12-CXCR4 axis results in the
recruitment of b-arrestin-2 to the carboxy terminus of CXCR4
[50]. To verify the inhibition of b-arrestin-2 recruitment by
candidate CXCR4 antagonists, we used a commercial CXCR4
assay (Tango; Invitrogen, Carlsbad, CA) [51,52]. Briefly, the
engineered cells (3610
4) were seeded in 96-well plates and
incubated overnight. DMSO or antagonists were added to the
cells for 30 minutes. Then CXCL12 (60 nM) was added and cells
were incubated for 5 hours. Then, LiveBLAzer
TM-FRET B/G
substrate mixture (24 ml) (Invitrogen) was added and incubated in
the dark at room temperature for 2 hours. Plates were then read
on a Synergy microplate reader (BioTek; Winooski, VT) with
excitation at 409 nm and emission at 460 nm and 530 nm.
Background fluorescence values for each emission wavelength
Figure 8. Top view of the predicted ligand binding site in the
crystal structure of human CXCR4. Green helices, TM1, 2, 3, 5, 6,
and 7 are shown. Upon binding, both chloroquine and hydroxychlor-
oquine interact favorably with the indicated residues (E32, N37, Y45,
W94, D97, H113, I185, D187, Y255, E288) shown in sticks. These residues
are within 5 A ˚ of the bound compound. However, the amino acid
residues at the CXCR4 binding site are oriented slightly different
depending on whether chloroquine or hydroxychloroquine bind. The
relative orientations of the CXCR4 amino acid residues that interact with
chloroquine and hydroxychloroquine are shown as green and cyan
sticks, respectively.
doi:10.1371/journal.pone.0031004.g008
Table 1. Predicted transmembrane regions of the human
CXCR4 receptor.
NT 1 MEGISIYTSDNYTEEMGSGDYDSMKEPCFREENANF 36 (36)
TM 1 37 NKIFLPTIYSIIFLTGIVGNGLVILVMG 64 (28)
LP 1 65 YQKKLRSMTD 74 (10)
TM 2 75 KYRLHLSVADLLFVITLPFWAVDA 98 (24)
LP 2 99 VANWYFG 105 (7)
TM 3 106 NFLCKAVHVIYTVNLYSSVLILAFISLDRYL 136 (31)
LP 3 137 AIVHATNSQRPRKLLA 152 (16)
TM 4 153 EKVVYVGVWIPALLLTIPDFIFANVSE 179 (27)
LP 4 180 ADDRYICDRFYPNDLWVVV 198 (19)
TM 5 199 FQFQHIMVGLILPGIVILSCYCIIISK 225 (27)
LP 5 226 LSHSKGHQKRKAL 238 (13)
TM 6 239 KTTVILILAFFACWLPYYIGISIDSFIL 266 (28)
LP 6 267 LEIIKQGCEFENTVHKW 283 (17)
TM 7 284 ISITEALAFFHCCLNPILYAFLG 306 (23)
CT 307 AKFKTSAQHALTSVSRGSSLKILSKGKRGGHSSVSTESESSSFHSS 352 (46)
Amino-terminal region (NT), Transmembrane region (TM), Loop region (LP),
Carboxy-terminal region (CT).
doi:10.1371/journal.pone.0031004.t001
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TM-FRET B/G substrate and subtracted from the
fluorescence values of the test wells. The background-corrected
fluorescence emission values at 460 nm were divided by the
530 nm value to obtain a 460 nm/530 nm ratio. The percentage
of b-arrestin recruitment of the sample was then calculated by
dividing the 460 nm/530 nm ratio of the testing well by the
460 nm/530 nm ratio of CXCL12 control well.
Calcium Flux Assay
A calcium flux assay was performed to assess anti-CXCR4
compounds using a Fluo-4 Direct calcium assay (Invitrogen) using
Molt-4 cells. These cells (8610
5) were seeded in 96-well plates with
26 Fluo-4 Direct calcium reagents. After incubation, candidate
antagonists were added to the wells and incubated at room
temperature for 1 hour. Changes in intracellular calcium concen-
tration upon addition of CXCL12 (50 nM) were monitored by
fluorescence excited at 494 nm and emitted at 516 nm using a
Synergy reader (BioTek). The sum of relative fluorescence units
(RFU) was calculated as the area under the equation derived from
continuous values of emission at 516 nm over a period of
90 seconds. The data represents three experiments performed in
duplicate.
Migration Assay
A migration assay to assess antagonists to CXCL12-mediated
chemotaxis was performed in 24-well cell culture plates with 8-mm
pore polycarbonate membranes (Millipore; Billerica, MA) using
the Jurkat cells. Briefly, cells (5610
6) were placed into the upper
chamber and CXCL12 (30 nM) in the lower chamber. Cell
migration was measured after incubation at 37uC for 5 hours. For
inhibition of migration, candidate antagonists and CXCL12 were
placed into the lower chamber. Migrating cells were harvested and
counted by hemacytometer. The percentage cell migration was
quantified as the ratio of the total number of cells in all of the wells
to the cells in the CXCL12 control wells (30 nM CXCL12), scaled
to the CXCL12 control well as 100% cell migration. These
experiments were performed in triplicate.
Cell Culture and Reagents for CXCR4 Signaling Assays
The established human pancreatic cancer cell lines PANC-1,
Hs-766T, AsPC-1, and MIAPaCa-2 were obtained from the
American Type Culture Collection (Manassas, VA) less than 5
years ago. All cells used for the experiments in this study were from
cryopreserved stores frozen in liquid nitrogen at the time that the
cell lines were commercially obtained. Polymerase chain reaction
(PCR) and direct sequencing were performed for K-ras and p53
mutations to verify the genotype of the cells. Cells were cultured in
recommended media and maintained at 37uC and 5% CO2.
Chloroquine and hydroxychloroquine were purchased from MP
Biomedical (Solon, OH).
Antagonism of ERK Phosphorylation
We have previously demonstrated CXCL12-driven increases in
ERK phosphorylation in pancreatic cancer cells [21]. CXCL12-
driven changes in ERK phosphorylation following pre-treatment
with chloroquine and hydroxychloroquine were assessed by
Western blot assay as described [21]. 50 mg of cell lysates were
resolved on a 12% sodium dodecyl sulfate (SDS)-polyacrylamide
gel and transferred to a polyvinylidene fluoride (PVDF) mem-
brane. Membranes were blocked in blocking buffer for 1 hour and
then probed with primary antibodies at 4uC overnight. After
probing with horseradish peroxidase conjugated secondary
antibodies, presence of specific proteins on the Western blot was
detected using ECL reagent (Thermo Scientific; Rockford, IL).
Relative immunoblot band intensities were quantified using
densitometry (Alpha Innotech; Santa Clara, CA).
Measurement of Cytotoxicity
Chloroquine and hydroxychloroquine (0.1–100 mM) were
tested for cytotoxic activity in PANC-1, Hs-766T, ASPC-1, and
MIAPaCa-2 cells. Compounds were incubated with cells for
72 hours and cytotoxicity was measured via cellular acid
phosphatase activity. In brief, cells were seeded in 96-well plates.
After 72 hours, media was removed. Para-Nitrophenyl phosphate
(pNPP) buffer (0.1 M sodium acetate [pH 5.5], 0.1% Triton x100,
10 mM pNPP [N4645, Sigma], phosphate-buffered solution) was
added to each well and cells were incubated at 37uC for 2 hours.
After 1 N NaOH was added to each well, plates were then read
using the SpectraMax M2 microplate reader at 405 nm
(Molecular Devices, Sunnyvale, CA). At least 3 independent
assays were performed for each cell line. The minimal inhibitory
concentration (IC50) at which K the cells were still viable was
determined for each compound in the 3 cell lines.
Cell Proliferation Assay
We have previously demonstrated CXCL12-driven increases in
pancreatic cancer cell proliferation [21]. CXCL12-driven cell
proliferation was measured following pre-treatment with chloro-
quine and hydroxychloroquine. CellTiter-Glo assay (Promega)
was used to detect cell proliferation as described [21]. In brief, cells
were plated in 96-well plates at a density of 5610
3 cells per well.
Cells were exposed to either chloroquine (0.1 mM) or hydroxy-
chloroquine (0.1 mM) for 30 minutes and then exposed to
CXCL12 (200 ng/ml) for 72 hours. For detection of the
luminescent signal, CellTiter-Glo reagent was added and the
plates were incubated and measured on a luminometer (Perkin-
Elmer, Shelton, CT). The level of proliferation of untreated cells
(i.e., control cells), was normalized to zero. The cell proliferation of
the treatment arms were then compared against these control cells.
At least 3 independent cell proliferation assays were performed for
each cell line.
Apoptosis Assay
The effects on CXCL12-driven anti-apoptosis were assessed
following exposure to chloroquine and hydroxychloroquine.
Pancreatic cancer cells (3610
5) were maintained in 6-well plates,
serum-starved for 24 hours, and then incubated with chloroquine
(0.1 mM) or hydroxychloroquine (0.1 mM) for 30 minutes. Cells
were then exposed to CXCL12 (200 ng/ml) for 48 hours.
Apoptotic cells were assessed by an Annexin V assay according
to the manufacturer’s protocol (Invitrogen). In brief, 1610
5 cells
were washed with cold PBS and re-suspended in 16 Annexin-
binding buffer to a final volume of 100 ml with Alexa Fluor 488,
annexin V, and propidium iodide. The mixture suspension was
gently vortexed and incubated for 15 minutes in the dark at room
temperature. Cells were then analyzed by flow cytometric assay.
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